pyrazines has been researched along with Pulmonary Arterial Hypertension in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (26.67) | 24.3611 |
| 2020's | 22 (73.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chin, KM; Doelberg, M; Feldman, J; Galiè, N; Gibbs, JSR; Grünig, E; Hoeper, MM; Martin, N; Mathai, SC; McLaughlin, VV; Perchenet, L; Poch, D; Saggar, R; Simonneau, G; Sitbon, O | 1 |
| Channick, R; Chin, KM; Coghlan, JG; Gaine, S; Galiè, N; Hoeper, MM; Hsu Schmitz, SF; Lang, IM; Lassen, C; McLaughlin, VV; Rubin, LJ; Sitbon, O; Tapson, VF | 1 |
| Channick, R; Chin, KM; Du Roure, C; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Jenner, B; Lang, IM; McLaughlin, VV; Rosenkranz, S; Rubin, LJ; Sitbon, O; Tapson, V | 1 |
| Akashi, K; Arinobu, Y; Ayano, M; Fukata, M; Higashioka, K; Horiuchi, T; Imabayashi, K; Kashiwado, Y; Kawano, S; Kimoto, Y; Mitoma, H; Niiro, H; Ono, N; Saiki, C; Yokoyama, T | 1 |
| Blanco, I; Cruz Utrilla, A; Del Pozo, R; Escribano-Subías, P; López-Meseguer, M | 1 |
| Braverman, LE; Farber, HW; Menon, AA; Sahay, S | 1 |
| Jin, Q; Liu, Z; Luo, Q; Xiong, C; Yan, L; Yu, X; Zhang, Y; Zhao, Q; Zhao, Z | 1 |
| Dahhan, T; Doerfler, S; Fortin, T; Kennedy, K; Parikh, KS; Rajagopal, S; Shelburne, N; Whitson, J | 1 |
| Benet, J; Bouvaist, H; Degano, B; Guillien, A; Picard, F; Piliero, N; Pison, C; Sitbon, O; Soumagne, T; Yanaka, K | 1 |
| Bialesova, L; Bouchard, A; Kinsella, BT; Mulvaney, EP; Reid, HM; Salvail, D | 1 |
| Lachant, DJ; White, RJ | 1 |
| Bukova, M; Chouvarine, P; Hansmann, G; Koestenberger, M; Meinel, K; Wåhlander, H | 1 |
| Goncharova, NS; Karelkina, EV; Moiseeva, OM; Simakova, MA | 1 |
| Burgos-Blasco, P; Diaz-Guimaraens, B; Dominguez-Santas, M; Ortega-Quijano, D; Saceda-Corralo, D; Suarez-Valle, A | 1 |
| Amin, EK; Austin, ED; Colglazier, E; Fineman, JR; Hemnes, AR; Leary, PJ; Nawaytou, H; Parker, C; Teitel, D | 1 |
| Burki, TK | 1 |
| Benza, RL; Raina, A; Verlinden, NJ; Walter, C | 1 |
| Fuchikami, C; Honda, Y; Kosugi, K; Kuramoto, K; Kuwano, K; Numakura, Y | 1 |
| Beghetti, M; Genecand, L; Lador, F; Wacker, J | 1 |
| Chakinala, MM; Chin, KM; Farber, HW; Hemnes, AR; Highland, KB; Kim, NH; McLaughlin, V; Narayan, V; Zhao, C | 1 |
| Axelsen, LN; Chin, KM; Ewert, R; Gall, H; Hsu Schmitz, SF; Klose, H; Parambil, J; Poch, D; Preston, IR; Seyfarth, HJ; Stein, C | 1 |
| Apostolopoulou, SC; Demerouti, EA; Karyofyllis, P | 1 |
| Channick, RN; Chin, KM; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, I; McLaughlin, VV; Preiss, R; Rubin, LJ; Sauter, R; Simonneau, G; Sitbon, O; Tapson, V | 1 |
| Huang, H; Kong, L; Luan, S; Qi, C; Wu, F | 1 |
| Akerström, F; Berenguel Senén, A; Escribano Subías, P; Lázaro Salvador, M; Martinez Mateo, V; Rodriguez Padial, L | 1 |
| Benza, RL; Chin, KM; Eggert, M; Farber, HW; Fisher, M; Fortin, TA; Fritz, JS; Frost, A; Janmohamed, M; Kim, NH; McConnell, JW; McEvoy, C; McLaughlin, V; Miller, CE; Pfister, T; Poch, D; Shiraga, Y | 1 |
| Airhart, S; Badie, N; Benza, R; Raina, A; Verlinden, N | 1 |
| Berlier, C; Lichtblau, M; Saxer, S; Schwarz, EI; Ulrich, S | 1 |
| Channick, R; Chin, KM; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Bock, MJ; Koo, R; Lo, J | 1 |
2 review(s) available for pyrazines and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?
Topics: Acetamides; Adult; Anticoagulants; Antihypertensive Agents; Cardiac Catheterization; Disease Progression; Diuretics; Drug Therapy, Combination; Echocardiography, Doppler; Endothelin Receptor Antagonists; Enzyme Activators; Exercise Tolerance; Female; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Prostaglandins; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pulmonary Edema; Pulmonary Veno-Occlusive Disease; Pyrazines; Pyrazoles; Pyrimidines; Retrospective Studies; Walk Test | 2019 |
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Humans; Pulmonary Arterial Hypertension; Pyrazines | 2021 |
8 trial(s) available for pyrazines and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyrazines; Pyrimidines; Sulfonamides; Tadalafil | 2021 |
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines | 2022 |
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
Topics: Acetamides; Antihypertensive Agents; Comorbidity; Double-Blind Method; Heart Failure; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines | 2022 |
Pharmacotherapy for pulmonary arterial hypertension.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines; Pyrimidines; Severity of Illness Index; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance | 2020 |
Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
Topics: Acetamides; Administration, Intravenous; Administration, Oral; Aged; Antihypertensive Agents; Cross-Over Studies; Drug Administration Routes; Female; Headache; Humans; Male; Middle Aged; Prospective Studies; Pulmonary Arterial Hypertension; Pyrazines | 2021 |
Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Male; Middle Aged; Morbidity; Prognosis; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Survival Rate | 2021 |
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Substitution; Drug Tolerance; Epoprostenol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prodrugs; Prospective Studies; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Treatment Outcome | 2019 |
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
Topics: Acetamides; Adolescent; Adult; Aged; Antihypertensive Agents; Arterial Pressure; Biomarkers; Double-Blind Method; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2019 |
20 other study(ies) available for pyrazines and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
Topics: Acetamides; Adult; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Iloprost; Lupus Erythematosus, Systemic; Pulmonary Arterial Hypertension; Pyrazines; Quality of Life | 2022 |
Effectiveness and persistence with selexipag in pulmonary arterial hypertension in the real-life setting.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines | 2023 |
Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Epoprostenol; Female; Goiter; Graves Disease; Hashimoto Disease; Humans; Hyperthyroidism; Male; Pulmonary Arterial Hypertension; Pyrazines; Thyroiditis, Autoimmune; Thyrotoxicosis | 2019 |
Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
Topics: Acetamides; Antihypertensive Agents; Arterial Pressure; Drug Substitution; Feasibility Studies; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Prospective Studies; Prostaglandins I; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Receptors, Epoprostenol; Time Factors; Treatment Outcome | 2020 |
Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution.
Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Pulmonary Arterial Hypertension; Pyrazines | 2020 |
NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
Topics: Acetamides; Animals; Antihypertensive Agents; Disease Models, Animal; Heart Ventricles; Hemodynamics; Humans; Hypertrophy, Right Ventricular; Male; Monocrotaline; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Rats; Rats, Inbred WKY; Receptors, Thromboxane; Sildenafil Citrate; Vascular Remodeling | 2020 |
Selexipag Use in Clinical Practice: Mind the Gap.
Topics: Acetamides; Consensus; Epoprostenol; Humans; Prostaglandins I; Pulmonary Arterial Hypertension; Pyrazines | 2020 |
Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Blood Pressure; Child; Female; Humans; Male; Prodrugs; Prospective Studies; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrazines; Treatment Outcome | 2020 |
[Experience with Selexipag to Treat Pulmonary Arterial Hypertension].
Topics: Acetamides; Humans; Pulmonary Arterial Hypertension; Pyrazines | 2020 |
Rosacea induced by selexipag in a patient with pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Humans; Pulmonary Arterial Hypertension; Pyrazines; Rosacea | 2020 |
Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?
Topics: Acetamides; Adolescent; Antihypertensive Agents; Asymptomatic Diseases; Bone Morphogenetic Protein Receptors, Type II; Cardiac Catheterization; Disease Progression; Dyspnea; Echocardiography; Exercise Tolerance; Female; Genetic Testing; Heterozygote; Humans; Male; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Syncope; Vasodilator Agents | 2020 |
A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
Topics: Acetamides; Antihypertensive Agents; Female; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines | 2021 |
The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetamides; Animals; Cell Proliferation; Collagen Type I; Disease Models, Animal; Heart Ventricles; Hemodynamics; Hypertrophy, Right Ventricular; Hypoxia; Indoles; Lung; Male; Pulmonary Arterial Hypertension; Pyrazines; Pyrroles; Rats, Sprague-Dawley; Receptors, Epoprostenol; Systole; Vascular Remodeling | 2020 |
Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
Topics: Acetamides; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Prospective Studies; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Receptors, Prostaglandin; Treatment Outcome; United States | 2021 |
Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
Topics: Acetamides; Adult; Antihypertensive Agents; Eisenmenger Complex; Female; Humans; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines; Receptors, Epoprostenol | 2021 |
Ligustrazine Suppresses Platelet-Derived Growth Factor-BB-Induced Pulmonary Artery Smooth Muscle Cell Proliferation and Inflammation by Regulating the PI3K/AKT Signaling Pathway.
Topics: Animals; Becaplermin; Cell Cycle; Cell Proliferation; China; Disease Models, Animal; Inflammation; Male; Myocytes, Smooth Muscle; Phosphatidylinositol 3-Kinases; Plant Extracts; Proto-Oncogene Proteins c-akt; Pulmonary Arterial Hypertension; Pyrazines; Rats; Rats, Sprague-Dawley | 2021 |
Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.
Topics: Acetamides; Antihypertensive Agents; Drug Substitution; Drug Therapy, Combination; Epoprostenol; Female; Humans; Infusion Pumps; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Tadalafil; Vasodilator Agents | 2019 |
Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Drug Substitution; Epoprostenol; Equipment Design; Female; Humans; Middle Aged; Monitoring, Physiologic; Prodrugs; Pulmonary Arterial Hypertension; Pulmonary Artery; Pulmonary Wedge Pressure; Pyrazines; Remote Sensing Technology | 2019 |
Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Topics: Acetamides; Aged; Antihypertensive Agents; Chronic Disease; Cohort Studies; Drug Therapy, Combination; Echocardiography; Endothelin Receptor Antagonists; Enzyme Activators; Exercise Test; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Oxygen Consumption; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Embolism; Pyrazines; Quality of Life; Retrospective Studies; Soluble Guanylyl Cyclase; Tricuspid Valve; Walk Test | 2019 |
Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
Topics: Acetamides; Administration, Intravenous; Administration, Oral; Antihypertensive Agents; Echocardiography; Enteral Nutrition; Epoprostenol; Humans; Infant, Newborn; Infusions, Intravenous; Male; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Receptors, Prostaglandin | 2019 |